Kordata Launches To Advance Neurotech-Powered Clinical Trials

InnovationHealthcareKordata Launches To Advance Neurotech-Powered Clinical TrialsByNaveen Rao,Contributor.Forbes contributors publish independent expert analyses and insights. I’m an analyst covering neurotech's impact on business and society.Follow AuthorMay 21, 2026, 12:02pm EDT--:-- / --:--This voice experience is generated by AI. Learn more.This voice experience is generated by AI. Learn more.The Kordata Dynamics team at the Neural Frontiers conference in Bakersfield, CAKordata DynamicsKordata Dynamics has emerged from stealth to pursue a $26 billion opportunity to advance the clinical trials backlog across central nervous system (CNS) therapeutics with a combination of patient-facing neurotechnology and an enterprise B2B playbook.BIOS Health supplied the core IP and business foundation, and retains majority ownership of the spinout. The two firms also share the same founder, Emil Hewage, who will lead Kordata as CEO alongside president Dawn McCollough, a former Biogen and Novartis executive behind 15,000 clinical trials. I spoke with Hewage to learn about Kordata’s approach to bringing neural data into life sciences. Business Model: Kordata is partnering with large health systems and academic medical centers to enable new trial sites for pharmaceutical or life sciences companies. In addition to volume-based licensing revenue on deploying tools to these hospital and research networks, they will earn fees on new clinical trial sponsorships at partner sites.Target Market: With their partners, they will target life sciences firms, Hewage told me, “specifically those that have very precise products, with tight dosing ranges or unique inclusion criteria, who are designing novel trials.” Beyond the initial focus on drug discovery and device optimization in Alzheimer’s, Parkinson’s, and Epilepsy, he spoke to the unmet needs in drug resistant chronic diseases in cardiology, immunology, and beyond. Tech Stack as a Service: Hewage describes their health system partne...